Risk factors for breast cancer

Some risk factors can be changed

Risk factors for breast cancer may be divided into preventable and non-preventable. Their study belongs in the field of epidemiology. Breast cancer, like other forms of cancer, can result from multiple environmental and hereditary risk factors. The term environmental, as used by cancer researchers, means any risk factor that is not genetically inherited.

For breast cancer, the list of environmental risk factors includes the individual person's development, exposure to microbes, "medical interventions, dietary exposures to nutrients, energy and toxicants, ionizing radiation, and chemicals from industrial and agricultural processes and from consumer products...reproductive choices, energy balance, adult weight gain, body fatness, voluntary and involuntary physical activity, medical care, exposure to tobacco smoke and alcohol, and occupational exposures, including shift work" as well as "metabolic and physiologic processes that modify the body's internal environment." ^[1] Some of these environmental factors are part of the physical environment, while others (such as diet and number of pregnancies) are primarily part of the social, cultural, or economic environment. ^[1]

Although many epidemiological risk factors have been identified, the cause of any individual breast cancer is most often unknowable. Epidemiological research informs the patterns of breast cancer incidence across certain populations, but not in a given individual. Approximately 5% of new breast cancers are attributable to hereditary syndromes, and well-established risk factors accounts for approximately 30% of cases. ^[2] A 2024 review found that there is a convincing association between increased breast cancer risk with high BMI and weight gain in postmenopausal women and a decreased risk from high fiber intake and high sex hormone-binding globulin levels. ^[3]

Age

Age is the biggest risk factor for breast cancer

The risk of getting breast cancer increases with age. A woman is more than 100 times more likely to develop breast cancer in her 60s than in her 20s. ^[4] The risk over a woman's lifetime is, according to one 2021 review, approximately "1.5% risk at age 40, 3% at age 50, and more than 4% at age 70." ^[5]

In the United States, about one in eight women (~13%) and one in 800 men (~0.13%) will be diagnosed with breast cancer at some point during their lives. ^{[6] [7]} These numbers can vary depending on the location one grows up in, as numerous environmental factors can increase or decrease risk. ^[5]

Though the probability of breast cancer increases with age, breast cancer tends to be more aggressive in younger people. ^[8]

Sex

Male individuals have a much lower risk of developing breast cancer than females. In developed countries, about 99% of breast cancer cases are diagnosed in female patients; in a few African countries, which represent the highest incidence of male breast cancer, males account for 5–15% of cases. ^[4] The rate of male breast cancer appears to be rising somewhat. ^[9]

Male breast cancer patients tend to be older than female ones. ^[4] They are more likely to be diagnosed with hormone-receptor positive tumors, with about six out of seven cases being estrogen-receptor positive. ^[4] The overall prognosis is worse for male than for female patients. ^[4]

Heredity

Further information: Cancer syndrome and Hereditary breast–ovarian cancer syndrome

The United Kingdom, being a member of the International Cancer Genome Consortium, is leading efforts to map breast cancer's complete genome.

BRCA1 and BRCA2

In 5% of breast cancer cases, there is a strong inherited familial risk. ^[10]

Two autosomal dominant genes, BRCA1 and BRCA2 , account for most of the cases of familial breast cancer. Women who carry a harmful BRCA mutation have a 60% to 80% risk of developing breast cancer in their lifetimes. ^[10] Other associated malignancies include ovarian cancer and pancreatic cancer. If a mother or a sister was diagnosed breast cancer, the risk of a hereditary BRCA1 or BRCA2 gene mutation is about two-fold higher than those women without a familial history. Commercial testing for BRCA1 and BRCA2 gene mutations has been available in most developed countries since at least 2004.

In addition to the BRCA genes associated with breast cancer, the presence of NBR2 , near breast cancer gene 1, has been discovered, and research into its contribution to breast cancer pathogenesis is ongoing. ^[11]

Other genes

Hereditary non-BRCA1 and non-BRCA2 breast tumors (and even some sporadic carcinomas) are believed to result from the expression of weakly penetrant but highly prevalent mutations in various genes. For instance, polymorphism has been identified in genes associated to the metabolism of estrogens and/or carcinogens (Cytochrome P450, family 1, member A1, CYP1B1, CYP17A1, CYP19, Catechol-O-methyltransferase, N-acetyltransferase 2, Glutathione S-transferase Mu 1, GSTP1, GSTT, . . . ), to estrogen, androgen and vitamin D action (ESR1, AR, VDR), to co-activation of gene transcription (AIB1), to DNA damage response pathways (CHEK2, HRAS1, XRCC1, XRCC3, XRCC5). ^[12] Sequence variants of these genes that are relatively common in the population may be associated with a small to moderate increased relative risk for breast cancer. Combinations of such variants could lead to multiplicative effects. Sporadic cancers likely result from the complex interplay between the expression of low penetrance genes (risk variants) and environmental factors. However, the suspected impact of most of these variants on breast cancer risk should, in most cases, be confirmed in large populations studies. Indeed, low penetrance genes cannot be easily tracked through families, as is true for dominant high-risk genes. ^[12]

Part of the hereditary non-BRCA1 and non-BRCA2 breast tumors may be associated to rare syndromes, of which breast cancer is only one component. Such syndromes result notably from mutations in TP53 (Li–Fraumeni syndrome), ATM (ataxia–telangiectasia), STK11/LKB1(Peutz–Jeghers syndrome), PTEN (Cowden syndrome).

RAB11FIP1, ^[13] TP53, PTEN and rs4973768 are also associated with increased risk of breast cancer. rs6504950 is associated with lower risk of breast cancer. ^{[14] [ better source needed ]}

Mutations in RAD51C confer an increased risk for breast and ovarian cancer. ^[15]

Prior cancers

People who have previously been diagnosed with breast, ovarian, uterine, or bowel cancer have a higher risk of developing breast cancer in the future. ^[4] Mothers of children with soft-tissue sarcoma may have an increased risk of breast cancer. ^[4]

Dietary factors

The Western dietary pattern is associated with an increased risk of breast cancer. ^{[16] [17]}

Alcohol

Main article: Alcohol and breast cancer

There is strong evidence that alcohol consumption increases risk of breast cancer. ^{[18] [19] [20] [21] [22]}

Calcium

Several reviews have found a weak inverse association between dietary calcium intake and breast cancer risk. ^{[23] [24]} The World Cancer Research Fund International and American Institute for Cancer Research have stated that there is limited evidence that diets high in calcium might decrease the risk of breast cancer. ^{[19] [25]}

Fruits and vegetables

High total dietary fiber consumption and total fruit and vegetable consumption is associated with a reduced risk of breast cancer. ^{[26] [27]}

Meat

High total processed meat and red meat consumption are associated with increased breast cancer risk. ^{[16] [28] [29]}

Saturated fat

Several reviews of case–control studies have found that saturated fat intake is associated with increased breast cancer risk. ^{[16] [30] [31]}

Sugar

Sugar consumption does not cause cancer. ^{[32] [33]} The National Breast Cancer Foundation have stated that "eating too much of any food can contribute to weight gain, obesity, and health issues, which can in turn increase breast cancer risk, but there is no direct link between sugar and breast cancer. Consuming sugar in moderation as part of a healthy diet does not cause breast cancer". ^[34]

Obesity and lack of exercise

Gaining weight after menopause can increase a woman's risk. A 2006 study found that putting on 9.9 kg (22 lbs) after menopause increased the risk of developing breast cancer by 18%. ^{[35] [ better source needed ]} Lack of exercise has been linked to breast cancer by the American Institute for Cancer Research. ^[36]

Obesity has been linked to an increased risk of developing breast cancer by many scientific studies. ^[37] There is evidence to suggest that excess body fat at the time of breast cancer diagnosis is associated with higher rates of cancer recurrence and death. ^[37] Furthermore, studies have shown that obese women are more likely to have large tumors, greater lymph node involvement, and poorer breast cancer prognosis with 30% higher risk of mortality. ^[38]

Weight gain after diagnosis has also been linked to higher rates of breast cancer recurrence or mortality although this finding is not consistent. ^[37] Weight gain is often less severe with newer chemotherapy treatments but one study found a significant risk of breast cancer mortality in women who gained weight compared to those who maintained their weight. ^[39] However, other cohort studies and recent clinical trials have not shown a significant relationship between weight gain after diagnosis and breast cancer mortality. ^{[37] [40]}

Weight loss after diagnosis has not been shown to decrease the risk of breast cancer recurrence or mortality. ^[37] However, physical activity after breast cancer diagnosis has shown some associations with reducing breast cancer recurrence and mortality independent of weight loss. ^[41] Data for both weight loss and physical activity and the effect on breast cancer prognosis is still lacking. ^[37]

There is debate as to whether the higher rate of breast cancer associated with obesity is due to a biological difference in the cancer itself, or differences in other factors such as health screen practices. ^{[42] [ better source needed ]} It has been suggested that obesity may be a determinant for breast cancer screening by mammography. Seventeen scientific studies in the United States have found that as obesity increases in women over 40 years of age the rate of mammography reported decreases significantly. ^[43] When stratified by race (white vs. black) there was a stronger relationship between obesity and lack of mammography screening among white women. ^[43] Another study also found lower rates of mammography among those who were overweight and obese compared to those women who were of normal body mass index—this effect was only seen in white women. ^[44] Obese women are more likely to list pain associated with mammograms as a reason for not getting screened; however, leaner women also list this as a reason for avoiding mammograms. ^[45] Other reasons obese women may avoid mammography are due to lack of insurance, low income, or embarrassment at the procedure, although when these factors are accounted for, the effect of lower rates of screening are still significant. ^[45] In contrast, other studies have shown that mammography patterns did not differ among women who were obese compared to those at a healthy weight indicating that there may be biological differences in cancer presentation between these groups. ^[46]

Hormones

Persistently increased blood levels of estrogen are associated with an increased risk of breast cancer, as are increased levels of the androgens androstenedione and testosterone (which can be directly converted by aromatase to the estrogens estrone and estradiol, respectively). Increased blood levels of progesterone are associated with a decreased risk of breast cancer in premenopausal women. ^[47] A number of circumstances which increase exposure to endogenous estrogens including not having children, delaying first childbirth, not breastfeeding, early menarche (the first menstrual period) and late menopause are suspected of increasing lifetime risk for developing breast cancer. ^[48]

However, not only sex hormones but also insulin levels are positively associated with the risk of breast cancer. ^[49]

Pregnancy, childbearing and breastfeeding

Lower age of first childbirth, compared to the average age of 24, ^[50] having more children (about 7% lowered risk per child), and breastfeeding (4.3% per breastfeeding year, with an average relative risk around 0.7 ^{[51] [52]} ) have all been correlated to lowered breast cancer risk in premenopausal women, but not postmenopausal women, in large studies. ^[53] Women who give birth and breastfeed by the age of 20 may have even greater protection. ^[54] In contrast, for instance, having the first live birth after age 30 doubles the risk compared to having first live birth at age less than 25. ^[55] Never having children triples the risk. ^[55] The studies have found that these risk factors become less material as a woman reaches menopause, i.e. that they affect risk of breast cancer prior to menopause but not after it. In balancing premenopausal reductions in risk from childbirth and lactation, it is important also to consider the risks involved in having a child.

Hormonal contraception

Hormonal contraceptives may produce a slight increase in the risk of breast cancer diagnosis among current and recent users, but this appears to be a short-term effect. In 1996 the largest collaborative reanalysis of individual data on over 150,000 women in 54 studies of breast cancer found a relative risk (RR) of 1.24 of breast cancer diagnosis among current combined oral contraceptive pill users; 10 or more years after stopping, no difference was seen. Further, the cancers diagnosed in women who had ever used hormonal contraceptives were less advanced than those in nonusers, raising the possibility that the small excess among users was due to increased detection. ^{[56] [57]} The relative risk of breast cancer diagnosis associated with current and recent use of hormonal contraceptives did not appear to vary with family history of breast cancer. ^[58] Some studies have suggested that women who began using hormonal contraceptives before the age of 20 or before their first full-term pregnancy are at increased risk for breast cancer, but it is not clear how much of the risk stems from early age at first use, and how much stems from use before the first full-term pregnancy. ^[59]

Hormone replacement therapy

Data exist from both observational and randomized clinical trials regarding the association between menopausal hormone replacement therapy (menopausal HRT) and breast cancer. The largest meta-analysis (1997) of data from 51 observational studies, indicated a relative risk of breast cancer of 1.35 for women who had used HRT for five or more years after menopause. ^[60] The estrogen-plus-progestin arm of the Women's Health Initiative (WHI), a randomized controlled trial, which randomized more than 16,000 postmenopausal women to receive combined hormone therapy or placebo, was halted early (2002) because health risks exceeded benefits. One of the adverse outcomes prompting closure was a significant increase in both total and invasive breast cancers (hazard ratio = 1.24) in women randomized to receive estrogen and progestin for an average of five years. ^[61] HRT-related breast cancers had adverse prognostic characteristics (more advanced stages and larger tumors) compared with cancers occurring in the placebo group, and HRT was also associated with a substantial increase in abnormal mammograms. Short-term use of hormones for treatment of menopausal symptoms appears to confer little or no breast cancer risk. ^[58] A correlation was found between the use of hormonal contraceptives and subsequent reliance on hormone replacement therapy. ^[59]

Oophorectomy and mastectomy

Main article: BRCA mutation

Prophylactic oophorectomy (removal of ovaries) and mastectomy in individuals with high-risk mutations of BRCA1 or BRCA2 genes reduces the risk of developing breast cancer as well as reducing the risk of developing ovarian cancer. Because of the complex balance of benefits and risks of prophylactic surgery, it is recommended only in very specific cases, such as those where high-risk gene mutations are detected. ^[62]

Hormonal therapy

Main article: Hormonal therapy (oncology)

Hormonal therapy has been used for chemoprevention in individuals at high risk for breast cancer. Overall it is recommended only in very special circumstances. In 2002, a clinical practice guideline by the US Preventive Services Task Force (USPSTF) recommended that "clinicians discuss chemoprevention with women at high risk for breast cancer and at low risk for adverse effects of chemoprevention" with a grade B recommendation. ^{[63] [64] [65] [66]}

Selective estrogen receptor modulators (SERMs)

The 2002 USPSTF guidelines were based on studies of SERMs from the MORE, BCPT P-1, and Italian trials. ^[67] In the MORE trial, the relative risk reduction for raloxifene was 76%. ^[68] The P-1 preventative study demonstrated that tamoxifen can prevent breast cancer in high-risk individuals. The relative risk reduction was up to 50% of new breast cancers, though the cancers prevented were more likely estrogen-receptor positive (this is analogous to the effect of finasteride on the prevention of prostate cancer, in which only low-grade prostate cancers were prevented). ^{[69] [70]} The Italian trial showed benefit from tamoxifen. ^[71]

Additional randomized controlled trials have been published since the guidelines. The IBIS trial found benefit from tamoxifen. ^[72] In 2006, the NSABP STAR trial demonstrated that raloxifene had equal efficacy in preventing breast cancer compared with tamoxifen, but that there were fewer side effects with raloxifene. ^[73] The RUTH Trial concluded that "benefits of raloxifene in reducing the risks of invasive breast cancer and vertebral fracture should be weighed against the increased risks of venous thromboembolism and fatal stroke". ^[74] On September 14, 2007, the US Food and Drug Administration approved raloxifene (Evista) to prevent invasive breast cancer in postmenopausal women. ^[75]

Endocrine disruptors

Many xenoestrogens (industrially made estrogenic compounds) and other endocrine disruptors are potential risk factors of breast cancer.

Diethylstilbestrol (DES) is a synthetic form of estrogen. It has been used between the early 1940s and 1971. Pregnant women took DES to prevent certain pregnancy complications. However, it also increased their risk of breast cancer. It also increased the risk of breast cancer in the prenatally exposed daughters after the age of 40. ^[76]

Factors in the physical environment

According to a review, the main mechanisms by which environmental compounds increase breast cancer risk are acting like hormones, especially estrogen, or affecting susceptibility to carcinogenesis. ^[77] The evidence to date generally supports an association between breast cancer and polycyclic aromatic hydrocarbons (PAHs) and polychlorinated biphenyls (PCBs). Dioxins and organic solvents, on the other hand, have only shown an association in sparse and methodologically limited studies, but are suggestive of an association. ^[77] Overall, however, evidence is still based on a relatively small number of studies. ^[77]

Xenoestrogens

Main article: Xenoestrogens

Many xenoestrogens (industrially made estrogenic compounds) are endocrine disruptors, and potential risk factors of breast cancer. Endocrine disruption is the hypothesis that some chemicals in the body, such as Bisphenol A, are capable of interfering with the production, processing, and transmission of hormones. ^[78]

A substantial and growing body of evidence indicates that exposures to certain toxic chemicals and hormone-mimicking compounds including chemicals used in pesticides, cosmetics and cleaning products contribute to the development of breast cancer.

The increasing prevalence of these substances in the environment may explain the increasing incidence of breast cancer, though direct evidence is sparse.

Bisphenol A

Main article: Bisphenol A

Exposure to bisphenol A causes breast cancer.

Bisphenol A (BPA) is a chemical compound used in the production of plastics found in numerous commercial products, including laptops, baby bottles, food containers, water main pipes, and laboratory and hospital equipment. BPA was first produced in 1891, but its estrogenic properties went undiscovered until the mid-1930s. Today it is considered a xenoestrogen, and it functions as an endocrine disruptor that interferes with hormones in the body and disrupts the normal functioning of the endocrine system. At very low levels the FDA has long considered BPA in food to be safe, but this has been challenged over the years as more information is discovered regarding the effects of the chemical. ^[80]

Rats exposed prenatally to environmentally relevant doses of BPA show an increased number of intraductal hyperplasias (precancerous lesions) in mammary glands that appear during adulthood, while high doses induce the development of carcinomas in breast tissue. Animals exposed to BPA during fetal life develop palpable tumors, and all studies show an increased susceptibility to mammary gland neoplasia that manifests during adulthood. Exposure of mouse dams to environmentally relevant levels of BPA during organogenesis results in considerable alterations in the mammary gland. It was concluded that perinatal exposure to low doses of BPA results in altered mammary gland morphogenesis, induction of precancerous lesions, and carcinoma in situ. ^[79]

A study sought to determine whether early exposure to BPA could accelerate mammary carcinogenesis in a dimethylbenzanthracene (DMBA) model of rodent mammary cancer. In the study, scientists exposed neonatal/prebubertal rats to BPA via lactation from nursing dams treated orally with 0, 25, and 250 μg BPA/kg body weight/day. For tumorigenesis studies, female offspring were exposed to 30 mg DMBA/kg body weight at 50 days of age. DMBA induces mammary tumors and allows chemicals that predispose for mammary cancer to increase the number of mammary adenocarcinomas. The results of the study showed that female rats in the control, BPA 25, and BPA 250 groups administered DMBA exhibited a BPA dose-dependent increase in mammary tumors. The groups had 2.84, 3.82, and 5.00 mammary tumors per rat respectively. Treatment with BPA also reduced tumor latency, with the median tumor latency of 65, 53, and 56.5 days for 0, BPA 25, and BPA 250 groups respectively. Maternal exposure to BPA during lactation decreased time to first tumor latency and increased the number of DMBA-induced mammary tumors in female offspring. If these effects found in rodents carry over to humans, even minimal exposure to BPA could cause an increased risk for breast cancer. ^[81]

The elevated incidence of breast cancer in women has been associated with prolonged exposure to high levels of estrogens. Xenoestrogens such as BPA have the capacity to perturb normal hormonal actions. This study provides evidence of the estrogenic effects of BPA. In this study the human breast epithelial cells MCF-10F were treated with 10-3 M, 10-4 M, 10-5 M and 10-6 M BPA continuously for two weeks. The cells treated with 10-3 M BPA died on the second day of treatment. The concentration of 10-4 M BPA was also toxic for the breast epithelial cells, and they died on the fourth day of treatment. This data indicated that these concentrations of BPA are toxic for MCF-10F cells. After the two-week observation period it was seen that the cells formed a high percentage of duct-like structures in collagen. MCF-10F cells treated with 10-5 M and 10-6 M BPA formed a high percentage of solid masses, 27% and 20% respectively. This data indicates that BPA is able to induce neoplastic transformation of human breast epithelial cells. Epigenetic changes are involved in the early stages of cancer initiation by altering ductulogenesis. BPA was able to induce transformation of human breast MCF-10F epithelial cells. After treatment with BPA, the cells produced fewer collagen tubules and more solid masses. ^[82]

Consumer groups recommend that people wishing to lower their exposure to bisphenol A avoid canned food and polycarbonate plastic containers (which shares resin identification code 7 with many other plastics) unless the packaging indicates the plastic is bisphenol A-free. ^[83] The US National Toxicology Panel recommends avoiding microwaving food in plastic containers, putting plastics in the dishwasher, or using harsh detergents on plastics, to avoid leaching. ^[84]

Aromatic amines

Aromatic amines are chemicals that are produced when products such as dyes, polyurethane products, and certain pesticides are made. They are also found in cigarette smoke, fuel exhaust, and in overcooked, burned meat. The three types of aromatic amines, monocyclic, polycyclic, and heterocyclic, have all been found in recent studies of breast health. Monocyclic amines have been found to cause mammary cancer in rats. Studies have shown that women who eat higher amounts of overcooked meat, meaning more exposure to heterocyclic amines, have also been diagnosed with more post-menopausal breast cancer. Heterocyclic amines also have the ability to copy estrogen and in laboratory studies have been found to encourage the growth of cancerous tumors on human tissue. ^[85]

Benzene

Multiple studies point to a correlation between benzene exposure and breast cancer risk.

Benzene is a petrochemical solvent. Benzene exposure mostly originates from air pollution resulting from industrial burning, exhaust and gas fumes, as well as cigarette smoke. Petroleum, its distillates such as gasoline, auto and truck exhausts also contain benzene. The International Agency for Research on Cancer and the American National Toxicology Program have labeled benzene as a definite human carcinogen. Multiple studies point to a correlation between benzene exposure and breast cancer risk. Laboratory studies on mice have shown that a high level of benzene exposure can lead to mammary cancer. ^[85]

DDT

Main article: DDT § Breast cancer

Although the pesticide DDT was banned in the United States in the 1970s, ^[86] studies have shown that there are still trace amounts found in certain agricultural products, as well as in human and animal milk. ^[87] While individual studies have come to conflicting conclusions, the most recent reviews of all the evidence conclude that exposure to DDT before puberty increases the risk of breast cancer later in life. ^{[88] [89]}

Ethylene oxide

Ethylene oxide is a chemical that can be found in some personal care products, mainly in the form of fragrance. It is also used for the sterilization of various medical objects. The US National Toxicology Program has labeled ethylene oxide as a definite human and animal carcinogen. A study done by the US National Institute for Occupational Safety and Health, including 7,576 women, found a direct correlation between breast cancer rates and exposure to ethylene oxide during medical sterilization processes. Also, human breast cells put into contact with small amounts of ethylene oxide in a laboratory can lead to DNA damage of the breast tissue. ^[85]

Polycyclic aromatic hydrocarbons

Polycyclic aromatic hydrocarbons (PAHs) are chemical products of combustion from coal burners, fuel, cigarette smoke, and various other sources. PAHs are often found in the air and are breathed into the body. PAHs bioaccumulate easily and can copy the estrogen hormone. PAHs can also be genotoxic, meaning they have the ability to harm DNA. ^[85]

Vinyl chloride

Vinyl chloride is produced when PVC or polyvinyl chloride is made. PVC is found in plastic packaging, outerwear, plastic toys and other plastic products. Vinyl chloride can be found in cigarette smoke and the air around garbage and landfills. It can also be found in the wastewater when PVC is made. The US National Toxicology Program and the International Agency for Research on Cancer have both labeled vinyl chloride as a definite human carcinogen. ^[85]

Tobacco

See also: Women and smoking § Unique gender differences and health effects for Females

Until recently, most studies had not found an increased risk of breast cancer from active tobacco smoking. Beginning in the mid-1990s, a number of studies suggested an increased risk of breast cancer in both active smokers and those exposed to secondhand smoke compared to women who reported no exposure to secondhand smoke. ^[90] By 2005 enough evidence had accumulated for the California Environmental Protection Agency to conclude that breathing secondhand smoke causes breast cancer in younger, primarily premenopausal women. ^[91] The Agency concluded that the risk was increased by 70%, based on epidemiological studies and the fact that there are many mammary carcinogens in secondhand smoke. The following year (2006) the US Surgeon General identified the same risk increase and concluded that the evidence is "suggestive," one step below causal. ^[92] There is some evidence that exposure to tobacco smoke is most problematic between puberty and first childbirth. The reason that breast tissue appears most sensitive to chemical carcinogens in this phase is that breast cells are not fully differentiated until lactation. ^{[93] [94]} The likely reason that the older studies of active smoking did not detect risks associated with smoking was that they compared active smokers to all nonsmokers (which includes many passive smokers). The newer studies, which exclude passive smokers from the control group, generally show elevated risks associated with active as well as passive smoking.

Radiation

Women who have received high-dose ionizing radiation to the chest (for example, as treatments for other cancers) have a relative risk of breast cancer between 2.1 and 4.0. ^[90] The risk increases with increased dose. In addition, the risk is higher in women irradiated before age 30, when there is still breast development. ^[55]

Dioxins

Dioxins (most notably the polychlorinated dibenzodioxins) are chemicals that are produced when chlorinated products are burned, such as polyvinyl chloride (PVC). This occurs when chlorinated products are used in certain manufacturing industries. Dioxins are also added to the air when gasoline and diesel fuels break down. Dioxins are able to bioaccumulate, meaning that they settle and stay in human and animal fat for long periods of time. There are many different types of dioxins and only a few of them have been labeled by the Environmental Protection Agency as definite human carcinogens and endocrine hormone disruptors. Although dioxins float in the air, they eventually settle on plants and other vegetation surfaces. These plants and vegetation are them eaten by cows and other animals. Humans end up eating the produce, milk, eggs, and meat produced by animals that have consumed dioxin-covered vegetation. Dioxins are more harmful when ingested this way. Multiple studies have led to the idea that increased dioxin levels can increase one's risk for breast cancer. A study done in 1976 after a chemical plant explosion in Seveso, Italy, concluded that high dioxin level exposure in a woman's body correlated with a more than double chance of developing breast cancer. ^[85]

Light at night and disturbance of circadian rhythm

In 1978 Cohen et al. proposed that reduced production of the hormone melatonin might increase the risk of breast cancer and citing "environmental lighting" as a possible causal factor. ^[95] Researchers at the National Cancer Institute (NCI) and National Institute of Environmental Health Sciences conducted a study in 2005 that suggests that artificial light during the night can be a factor for breast cancer by disrupting melatonin levels. ^[96] According to a research in 2008, a reduced melatonin level in postmenopausal women is linked to a higher risk of breast cancer. ^[97]

In 2007, "shiftwork that involves circadian disruption" was listed as a probable carcinogen by the World Health Organization's International Agency for Research on Cancer. ^[98] Multiple studies have documented a link between night shift work and the increased incidence of breast cancer. ^{[99] [100] [101] [102]} A review of current knowledge of the health consequences of exposure to artificial light at night including the increased incidence of breast cancer and an explanation of the causal mechanisms has been published in the Journal of Pineal Research in 2007. ^[103]

Tonsillectomy

A systematic review and meta-analysis of eight studies revealed an association of prior tonsillectomy and risk of breast cancer in females. ^[104]

Ethnicity-related and socioeconomic factors

See also: Cultural differences in breast cancer diagnosis and treatment

Incidence and mortality vary with ethnic background and social status. Incidence rises with improving economic situation, while mortality is tied to low economic status. In the US incidence is significantly lower and mortality higher among black women; this difference appears to persist even after adjustment for economic status. It is currently unclear if significant ethnic differences in incidence and mortality persist after adjustment for economic status between women of white, Hispanic and Asian origin in the US. ^[105]

Several studies have found that black women in the US are more likely to die from breast cancer even though white women are more likely to be diagnosed with the disease. Even after diagnosis, black women are less likely to get treatment compared to white women. ^{[106] [107] [108]} Scholars have advanced several theories for the disparities, including inadequate access to screening, reduced availability of the most advanced surgical and medical techniques, or some biological characteristic of the disease in the African American population. ^[109] Some studies suggest that the racial disparity in breast cancer outcomes may reflect cultural biases more than biological disease differences. ^[110] However, the lack of diversity in clinical trials for breast cancer treatment may contribute to these disparities, with recent research indicating that black women are more likely to have estrogen receptor-negative breast cancers, which are not responsive to hormone treatments that are effective for most white women. ^[111] Research is currently ongoing to define the contribution of both biological and cultural factors. ^{[107] [112]}

Part of the differences in incidence attributable to race and economic status may be explained by past use of hormone replacement therapy. ^[113]

Factors with inconclusive research

1,3-Butadiene

1,3-Butadiene is an environmental factor that can be found in air pollution and can be produced by combustion engines, as well as petroleum refineries. It is found in cigarette smoke and is also used in the making and processing of certain synthetic rubber products and fungicides. The US National Toxicology Program has labeled 1,3-Butadiene as definite human carcinogen. The US Environmental Protection Agency (EPA) has stated that people are mainly put in contact with this chemical through the means of simple inhalation. ^[85]

Mammographic density

Mammographic density refers to the relative proportions of radiodense area compared to the radiolucent area on a mammogram, which is basically an x-ray of the breast. The radiodense area on a mammogram is white and is associated with ductal and lobular epithelium, connective tissue and fluid in the breast. The radiolucent area is dark gray or black and is associated with fat in the breast. High mammographic density is associated with a higher risk of developing breast cancer, but the reasons for this link are not certain and are being studied. ^{[114] [115]} Conversely, patients with very low mammographic breast density were found to hold a poorer prognosis irrespective of age, BMI and menopausal status. ^[116]

Red No. 3

Red No. 3 is a coloring agent used in some foods that has been found to increase the formation of certain tumors in rodents. ^[117] While results from one study using cultured human breast cancer cells indicated that Red No. 3 may cause DNA damage, ^[118] other studies have concluded that Red No. 3 does not cause DNA damage. ^[117]

Viruses

Several kinds of viruses with oncogenic potential are suspected to play a role or cause breast cancer. Among the three most commonly studied are the human papilloma virus (HPV), ^[119] mouse mammary tumour virus (MMTV) ^[120] and the Epstein-Barr virus (EBV). ^[120] A study published in 2011, reviewing 85 original molecular research investigations on the presence of one or more of these three viruses, found that only seven of the studies convincingly demonstrated the presence of an oncogenic virus biomarker, while twenty-five of the studies were able to show the absence of the virus studied, and the remaining studies were excluded due to shortcomings. Thus, the data from these investigations do not justify a conclusion as to whether HPV, MMTV, or EBV play a causal role in human breast cancer development. ^[121]

Humans are not the only mammals susceptible to breast cancer. Some strains of mice, namely the house mouse (Mus domesticus) are prone to breast cancer which is caused by infection with the mouse mammary tumour virus (MMTV or Bittner virus, for its discoverer, John Joseph Bittner), by random insertional mutagenesis. It is the only animal breast cancer with a known etiology. ^[121] These findings are taken to mean that a viral origin of human breast cancer is at least possible, though there is no definitive evidence to support the claim that MMTV causes human breast cancer. For example, there may be critical differences between cancer pathogenesis in mice and humans. A human homologue of the mammary virus has been described in 1971 and linked to human breast cancer in several small epidemiologic studies. ^{[122] [123]}

Factors with minimal or no impact

There is no significant association between first-trimester abortion and breast cancer risk. ^[124] There is no scientific evidence to prove that any kind of brassiere can cause cancer. ^{[125] [126]} The myth that breast cancer is linked with deodorant use has been widely circulated, and appears to originate from a spam email sent in 1999. ^{[127] [128]} There is, however, no evidence to support the existence of such a link. ^[129] There is no persuasive connection between fertility medications and breast cancer. ^[130]

History

In past centuries, the development of breast cancer was most commonly seen as divine punishment or a trial. From Ancient Greek medicine until the end of the 17th century, the dominant medical explanation was an imbalance of the four humors. ^[131] By the start of the 18th century, humoralism had generally been rejected. Many other theories were put forward, often related to sexual activity: In 1713, Bernardino Ramazzini said that nuns developed breast cancer at a higher rate than married women because they did not engage in sexual intercourse, and the "unnatural" lack of sexual activity caused instability of the breasts; others countered that the cause was frequently too much sexual activity. ^[132] Other theories from the 18th century included various sorts of problems with the movement of body fluids, such as lymphatic blockages, curdled breast milk or the transformation of pus left after an infection. ^[132]

In modern times, women are more likely to blame themselves, perhaps deciding that their diet, childbearing history, decision not to breastfeed, or level of exercise is the cause. ^[131]

See also

• Carcinogen § IARC classification of carcinogens
• Epidemiology of breast cancer
• Mouse models of breast cancer metastasis
• Silent Spring Institute

References

1. Institute of Medicine (2012). Breast Cancer and the Environment: A Life Course Approach (Institute of Medicine). Washington, D.C.: National Academies Press. pp. 52–53. doi:10.17226/13263. ISBN   978-0-309-22069-9.
2. Madigan MP, Ziegler RG, Benichou J, Byrne C, Hoover RN (November 1995). "Proportion of breast cancer cases in the United States explained by well-established risk factors". Journal of the National Cancer Institute. 87 (22): 1681–5. doi:10.1093/jnci/87.22.1681. PMID   7473816.
3. Yiallourou A, Pantavou K, Markozannes G, Pilavas A, Georgiou A, Hadjikou A, Economou M, Christodoulou N, Letsos K, Khattab E, Kossyva C, Constantinou M, Theodoridou M, Piovani D, Tsilidis KΚ, Bonovas S, Nikolopoulos GK. (2024). "Non-genetic factors and breast cancer: an umbrella review of meta-analyses". BMC Cancer. 24 (1): 903. doi: 10.1186/s12885-024-12641-8 . PMC   11282738 . PMID   39061008.
4. Margolese RG, Fisher B, Hortobagyi GN, Bloomer WD (2000). "118". In Bast RC, Kufe DW, Pollock RE, et al. (eds.). Cancer Medicine (5th ed.). Hamilton, Ontario: B.C. Decker. ISBN   978-1-55009-113-7 . Retrieved 27 January 2011.
5. Łukasiewicz, Sergiusz; Czeczelewski, Marcin; Forma, Alicja; Baj, Jacek; Sitarz, Robert; Stanisławek, Andrzej (2021-08-25). "Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review". Cancers. 13 (17): 4287. doi: 10.3390/cancers13174287 . ISSN   2072-6694. PMC   8428369 . PMID   34503097.
6. "Breast Cancer Risk in American Women - NCI". www.cancer.gov. 2020-12-17. Retrieved 2024-01-04.
7. "Breast Cancer Statistics | How Common Is Breast Cancer?". www.cancer.org. Retrieved 2024-01-04.
8. Zhu, Jie Wei; Charkhchi, Parsa; Adekunte, Shadia; Akbari, Mohammad R. (2023) [22 March]. "What Is Known about Breast Cancer in Young Women?". Cancers. 15 (6): 1917. doi: 10.3390/cancers15061917 . ISSN   2072-6694. PMC   10047861 . PMID   36980802.
9. Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN (July 2004). "Breast carcinoma in men: a population-based study". Cancer. 101 (1): 51–7. doi: 10.1002/cncr.20312 . PMID   15221988. S2CID   972345.
10. Malone KE, Daling JR, Thompson JD, O'Brien CA, Francisco LV, Ostrander EA (March 1998). "BRCA1 mutations and breast cancer in the general population: analyses in women before age 35 years and in women before age 45 years with first-degree family history". JAMA. 279 (12): 922–9. doi:10.1001/jama.279.12.922. PMID   9544766.
11. Auriol E, Billard LM, Magdinier F, Dante R (2005). "Specific binding of the methyl binding domain protein 2 at the BRCA1-NBR2 locus". Nucleic Acids Research. 33 (13): 4243–54. doi:10.1093/nar/gki729. PMC   1181861 . PMID   16052033.
12. Lacroix M, Leclercq G (February 2005). "The "portrait" of hereditary breast cancer". Breast Cancer Research and Treatment. 89 (3): 297–304. doi:10.1007/s10549-004-2172-4. PMID   15754129. S2CID   23327569.
13. Zhang J, Liu X, Datta A, Govindarajan K, Tam WL, Han J, et al. (August 2009). "RCP is a human breast cancer-promoting gene with Ras-activating function". The Journal of Clinical Investigation (Free full text). 119 (8): 2171–83. doi:10.1172/JCI37622. PMC   2719918 . PMID   19620787.
14. "Breast cancer gene 'could reduce risk'". The Daily Telegraph. London. 2009-03-30. Archived from the original on 2009-04-03. Retrieved 2010-05-22.
15. Meindl A, Hellebrand H, Wiek C, Erven V, Wappenschmidt B, Niederacher D, et al. (May 2010). "Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene". Nature Genetics. 42 (5): 410–4. doi:10.1038/ng.569. PMID   20400964. S2CID   23842635.
16. Dandamudi A, Tommie J, Nommsen-Rivers L, Couch S (2018). "Dietary Patterns and Breast Cancer Risk: A Systematic Review". Anticancer Research. 38 (6): 3209–3222. doi: 10.21873/anticanres.12586 . PMID   29848668. S2CID   44149964.
17. Xiao Y, Xia J, Li L, Ke Y, Cheng J, Xie Y, Chu W, Cheung P, Kim JH, Colditz GA, Tamimi RM, Su X (2019). "Associations between dietary patterns and the risk of breast cancer: a systematic review and meta-analysis of observational studies". Breast Cancer Res. 21 (1): 16. doi: 10.1186/s13058-019-1096-1 . PMC   6352362 . PMID   30696460.
18. Shield KD, Soerjomataram I, Rehm J (2016). "Alcohol Use and Breast Cancer: A Critical Review". Alcohol Clin Exp Res. 40 (6): 1166–1181. doi:10.1111/acer.13071. PMID   27130687.
19. "Breast cancer". World Cancer Research Fund International. Retrieved 2023-12-15.
20. Continuous Update Project Expert Report 2018. Alcoholic drinks and the risk of cancer (PDF) (Report). World Cancer Research Fund, American Institute for Cancer Research. 2018. Retrieved 2022-12-05.
21. "Alcohol and Cancer Risk Fact Sheet". National Cancer Institute . 2021-07-14. Retrieved 2023-12-15.
22. Papadimitriou N, Markozannes G, Kanellopoulou A, Critselis E, Alhardan S, Karafousia V, Kasimis JC, Katsaraki C, Papadopoulou A, Zografou M, Lopez DS, Chan DS, Kyrgiou M, Ntzani E, Cross AJ, Marrone MT, Platz EA, Gunter MJ, Tsilidis KK (2021). "An umbrella review of the evidence associating diet and cancer risk at 11 anatomical sites". Nature Communications. 12 (1): 4579. Bibcode:2021NatCo..12.4579P. doi:10.1038/s41467-021-24861-8. PMC   8319326 . PMID   34321471.
23. Hidayat K, Chen GC, Zhang R, Du X, Zou SY, Shi BM, Qin LQ (2016). "Calcium intake and breast cancer risk: meta-analysis of prospective cohort studies". Br J Nutr. 116 (1): 158–166. doi: 10.1017/S0007114516001768 . PMID   27170091. S2CID   31204875.
24. Wu Y, Huang R, Wang M, Bernstein L, Bethea TN, Chen C, Chen Y, Eliassen AH, Freedman ND, Gaudet MM, Gierach GL, Giles GG, Krogh V, Larsson SC, Liao LM, McCullough ML, Miller AB, Milne RL, Monroe KR, Neuhouser ML, Palmer JR, Prizment A, Reynolds P, Robien K, Rohan TE, Sandin S, Sawada N, Sieri S, Sinha R, Stolzenberg-Solomon RZ, Tsugane S, van den Brandt PA, Visvanathan K, Weiderpass E, Wilkens LR, Willett WC, Wolk A, Zeleniuch-Jacquotte A, Ziegler RG, Smith-Warner SA (2021). "Dairy foods, calcium, and risk of breast cancer overall and for subtypes defined by estrogen receptor status: a pooled analysis of 21 cohort studies". Am J Clin Nutr. 114 (2): 450–461. doi:10.1093/ajcn/nqab097. PMC   8326053 . PMID   33964859.
25. Diet, nutrition, physical activity and breast cancer (PDF) (Report). World Cancer Research Fund, American Institute for Cancer Research. 2018. Retrieved 2022-12-05.
26. Farvid MS, Spence ND, Holmes MD, Barnett JB (2020). "Fiber consumption and breast cancer incidence: A systematic review and meta-analysis of prospective studies". Cancer. 126 (13): 3061–3075. doi: 10.1002/cncr.32816 . PMID   32249416. S2CID   214809009.
27. Farvid MS, Barnett JB, Spence ND (2021). "Fruit and vegetable consumption and incident breast cancer: a systematic review and meta-analysis of prospective studies". Br J Cancer. 125 (2): 284–298. doi:10.1038/s41416-021-01373-2. PMC   8292326 . PMID   34006925.
28. Farvid MS, Stern MC, Norat T, Sasazuki S, Vineis P, Weijenberg MP, Wolk A, Wu K, Stewart BW, Cho E (2018). "Consumption of red and processed meat and breast cancer incidence: A systematic review and meta-analysis of prospective studies". Int J Cancer. 143 (11): 2787–2799. doi:10.1002/ijc.31848. PMC   8985652 . PMID   30183083.
29. Farvid MS, Sidahmed E, Spence ND, Mante Angua K, Rosner BA, Barnett JB (2021). "Consumption of red meat and processed meat and cancer incidence: a systematic review and meta-analysis of prospective studies". Eur J Epidemiol. 36 (9): 937–951. doi:10.1007/s10654-021-00741-9. PMID   34455534. S2CID   237343954.
30. Xia H, Ma S, Wang S, Sun G (2015). "Meta-Analysis of Saturated Fatty Acid Intake and Breast Cancer Risk". Medicine. 94 (52): e2391. doi:10.1097/MD.0000000000002391. PMC   5291630 . PMID   26717389.
31. Brennan SF, Woodside JV, Lunny PM, Cardwell CR, Cantwell MM (2017). "Dietary fat and breast cancer mortality: A systematic review and meta-analysis". Critical Reviews in Food Science and Nutrition. 57 (10): 1999–2008. doi:10.1080/10408398.2012.724481. PMID   25692500. S2CID   34098509.
32. "Does Sugar Cause Cancer?". American Society of Clinical Oncology. 2021. Archived from the original on October 1, 2023.
33. "Sugar and cancer – what you need to know". Cancer Research UK. 2023. Archived from the original on January 6, 2024.
34. "Myth: Consuming sugar causes breast cancer". 2024. Archived from the original on January 20, 2024.
35. "Weight link to breast cancer risk". BBC News . 2006-07-12. Retrieved 2023-12-15.
36. Nelson, Mya (3 November 2011). "New Research: Getting Up From Your Desk Can Put the "Breaks" on Cancer. Experts Urge Americans to Rethink Outdated Notions of Physical Activity. Press release from AICR 2011 annual meeting" (Press release). American Institute for Cancer Research. Archived from the original on 6 November 2011. Retrieved 7 December 2011.
37. Ligibel J (October 2011). "Obesity and breast cancer". Oncology. 25 (11): 994–1000. PMID   22106549.
38. Protani M, Coory M, Martin JH (October 2010). "Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis" (PDF). Breast Cancer Research and Treatment. 123 (3): 627–35. doi:10.1007/s10549-010-0990-0. PMID   20571870. S2CID   22281435.
39. Kroenke CH, Chen WY, Rosner B, Holmes MD (March 2005). "Weight, weight gain, and survival after breast cancer diagnosis". Journal of Clinical Oncology. 23 (7): 1370–8. doi: 10.1200/JCO.2005.01.079 . PMID   15684320.
40. Caan BJ, Emond JA, Natarajan L, Castillo A, Gunderson EP, Habel L, et al. (September 2006). "Post-diagnosis weight gain and breast cancer recurrence in women with early stage breast cancer". Breast Cancer Research and Treatment. 99 (1): 47–57. doi:10.1007/s10549-006-9179-y. PMID   16541317. S2CID   23361085.
41. Holmes MD, Chen WY, Feskanich D, Kroenke CH, Colditz GA (May 2005). "Physical activity and survival after breast cancer diagnosis". JAMA. 293 (20): 2479–86. doi: 10.1001/jama.293.20.2479 . PMID   15914748.
42. "Cure, Facts for Life Racial and Ethnic Differences" (PDF). Susan G. Komen.^{[ dead link ]}
43. Maruthur NM, Bolen S, Brancati FL, Clark JM (May 2009). "Obesity and mammography: a systematic review and meta-analysis". Journal of General Internal Medicine. 24 (5): 665–77. doi:10.1007/s11606-009-0939-3. PMC   2669867 . PMID   19277790.
44. Wee CC, McCarthy EP, Davis RB, Phillips RS (April 2004). "Obesity and breast cancer screening". Journal of General Internal Medicine. 19 (4): 324–31. doi:10.1111/j.1525-1497.2004.30354.x. PMC   1492197 . PMID   15061741.
45. Feldstein AC, Perrin N, Rosales AG, Schneider J, Rix MM, Glasgow RE (January 2011). "Patient Barriers to Mammography Identified During a Reminder Program". Journal of Women's Health. 20 (3): 421–428. doi:10.1089/jwh.2010.2195. PMC   3117308 . PMID   21275649.
46. Kerlikowske K, Walker R, Miglioretti DL, Desai A, Ballard-Barbash R, Buist DS (December 2008). "Obesity, mammography use and accuracy, and advanced breast cancer risk". Journal of the National Cancer Institute. 100 (23): 1724–33. doi:10.1093/jnci/djn388. PMC   2734114 . PMID   19033562.
47. Yager JD, Davidson NE (January 2006). "Estrogen carcinogenesis in breast cancer". The New England Journal of Medicine. 354 (3): 270–82. doi:10.1056/NEJMra050776. PMID   16421368. S2CID   5793142.
48. "What Are the Risk Factors for Breast Cancer?". American Cancer Society . 25 September 2014. Archived from the original on 29 February 2016. Retrieved 15 December 2023.
49. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE, et al. (January 2009). "Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women". Journal of the National Cancer Institute. 101 (1): 48–60. doi:10.1093/jnci/djn415. PMC   2639294 . PMID   19116382.
50. "Title" . Medscape .
51. McTiernan A, Thomas DB (September 1986). "Evidence for a protective effect of lactation on risk of breast cancer in young women. Results from a case-control study". American Journal of Epidemiology. 124 (3): 353–8. doi:10.1093/oxfordjournals.aje.a114405. PMID   3740036.
52. Byers T, Graham S, Rzepka T, Marshall J (May 1985). "Lactation and breast cancer. Evidence for a negative association in premenopausal women". American Journal of Epidemiology. 121 (5): 664–74. doi:10.1093/aje/121.5.664. PMID   4014158.
53. Collaborative Group on Hormonal Factors in Breast Cancer (October 1997). "Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer". Lancet. 350 (9084): 1047–59. doi: 10.1016/S0140-6736(97)08233-0 . PMID   10213546. S2CID   54389746.
54. Newcomb PA, Storer BE, Longnecker MP, Mittendorf R, Greenberg ER, Clapp RW, et al. (January 1994). "Lactation and a reduced risk of premenopausal breast cancer". The New England Journal of Medicine. 330 (2): 81–7. doi: 10.1056/NEJM199401133300201 . PMID   8259187.
55. Mitchell RS, Kumar V, Abbas AK, Fausto N, eds. (2007). "Chapter 19". Robbins Basic Pathology (8th ed.). Philadelphia: Saunders. ISBN   978-1-4160-2973-1.
56. Collaborative Group on Hormonal Factors in Breast Cancer (June 1996). "Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies". Lancet. 347 (9017): 1713–27. doi: 10.1016/S0140-6736(96)90806-5 . PMID   8656904. S2CID   36136756.
57. Collaborative Group on Hormonal Factors in Breast Cancer (September 1996). "Breast cancer and hormonal contraceptives: further results. Collaborative Group on Hormonal Factors in Breast Cancer". Contraception. 54 (3 Suppl): 1S–106S. doi:10.1016/s0010-7824(15)30002-0. PMID   8899264.
58. PDQ Cancer Genetics Editorial Board (2023-11-08). "Genetics of Breast and Gynecologic Cancers (PDQ)–Health Professional Version: Hormone replacement therapy". Genetics of Breast and Ovarian Cancer. National Cancer Institute . Retrieved 2023-12-15.
59. World Health Organization International Agency for Research on Cancer (1999). "Hormonal Contraception and Post-menopausal Hormonal Therapy" (PDF). IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. 72. Retrieved 12 March 2011.
60. Stahlberg C, Pederson AT, Lynge E, Ottesen B (July 2003). "Hormone replacement therapy and risk of breast cancer: the role of progestins". Acta Obstetricia et Gynecologica Scandinavica. 82 (7): 335–44. doi: 10.1034/j.1600-0412.2003.00551.x . PMID   12790856. S2CID   33887019.
61. Heiss G, Wallace R, Anderson GL, Aragaki A, Beresford SA, Brzyski R, et al. (March 2008). "Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin". JAMA. 299 (9): 1036–45. doi: 10.1001/jama.299.9.1036 . PMID   18319414.
62. Mau, Christine; Untch, Michael (2017). "Prophylactic Surgery: For Whom, When and How?". Breast Care. 12 (6): 379–384. doi:10.1159/000485830. ISSN   1661-3791. PMC   5803721 . PMID   29456469.
63. "Archived: Breast Cancer: Medications for Risk Reduction | United States Preventive Services Taskforce". www.uspreventiveservicestaskforce.org. Retrieved 2024-01-19.
64. "Guide to Clinical Preventive Services, Third Edition: Periodic Updates, 2000–2003". Agency for Healthcare Research and Quality. US Preventive Services Task Force. Retrieved 2007-10-07.
65. U.S. Preventive Services Task Force (July 2002). "Chemoprevention of breast cancer: recommendations and rationale". Annals of Internal Medicine. 137 (1): 56–8. doi:10.7326/0003-4819-137-1-200207020-00016. PMID   12093249. S2CID   10445937.
66. Kinsinger LS, Harris R, Woolf SH, Sox HC, Lohr KN (July 2002). "Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force". Annals of Internal Medicine. 137 (1): 59–69. doi:10.7326/0003-4819-137-1-200207020-00017. PMID   12093250. S2CID   8608388.
67. "Archived: Breast Cancer: Medications for Risk Reduction | United States Preventive Services Taskforce". www.uspreventiveservicestaskforce.org. Retrieved 2024-01-19.
68. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, et al. (June 1999). "The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation". JAMA. 281 (23): 2189–97. doi: 10.1001/jama.281.23.2189 . PMID   10376571.
69. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, et al. (November 2005). "Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study". Journal of the National Cancer Institute. 97 (22): 1652–62. doi: 10.1093/jnci/dji372 . PMID   16288118.
70. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. (September 1998). "Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study". Journal of the National Cancer Institute. 90 (18): 1371–88. doi: 10.1093/jnci/90.18.1371 . PMID   9747868.
71. Veronesi U, Maisonneuve P, Rotmensz N, Bonanni B, Boyle P, Viale G, et al. (May 2007). "Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy". Journal of the National Cancer Institute. 99 (9): 727–37. doi: 10.1093/jnci/djk154 . PMID   17470740.
72. Cuzick J, Forbes JF, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A (February 2007). "Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial". Journal of the National Cancer Institute. 99 (4): 272–82. doi: 10.1093/jnci/djk049 . PMID   17312304.
73. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. (June 2006). "Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial". JAMA. 295 (23): 2727–41. doi: 10.1001/jama.295.23.joc60074 . PMID   16754727.
74. Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, et al. (July 2006). "Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women". The New England Journal of Medicine. 355 (2): 125–37. doi:10.1056/NEJMoa062462. hdl: 2437/113085 . PMID   16837676.
75. "AFP: US approves Lilly's Evista for breast cancer prevention". Archived from the original on May 20, 2011 – via Google.
76. Palmer JR, Wise LA, Hatch EE, Troisi R, Titus-Ernstoff L, Strohsnitter W, et al. (August 2006). "Prenatal diethylstilbestrol exposure and risk of breast cancer". Cancer Epidemiology, Biomarkers & Prevention. 15 (8): 1509–14. doi: 10.1158/1055-9965.EPI-06-0109 . PMID   16896041. S2CID   7225182.
77. Brody JG, Moysich KB, Humblet O, Attfield KR, Beehler GP, Rudel RA (June 2007). "Environmental pollutants and breast cancer: epidemiologic studies". Cancer. 109 (12 Suppl): 2667–711. doi: 10.1002/cncr.22655 . PMID   17503436. S2CID   2620028.
78. Vogel SA (November 2009). "The politics of plastics: the making and unmaking of bisphenol a "safety"". American Journal of Public Health. 99 Suppl 3 (S3): S559-66. doi:10.2105/AJPH.2008.159228. PMC   2774166 . PMID   19890158.
79. Soto AM, Sonnenschein C (July 2010). "Environmental causes of cancer: endocrine disruptors as carcinogens". Nature Reviews. Endocrinology. 6 (7): 363–70. doi:10.1038/nrendo.2010.87. PMC   3933258 . PMID   20498677.
80. Vogel SA (November 2009). "The Politics of Plastics: The Making and Unmaking of Bisphenol A 'Safety'". American Journal of Public Health. 99 Suppl 3 (3): S559-66. doi:10.2105/AJPH.2008.159228. PMC   2774166 . PMID   19890158.
81. Jenkins S, Raghuraman N, Eltoum I, Carpenter M, Russo J, Lamartiniere CA (June 2009). "Oral exposure to bisphenol a increases dimethylbenzanthracene-induced mammary cancer in rats". Environmental Health Perspectives. 117 (6): 910–5. doi:10.1289/ehp.11751. PMC   2702405 . PMID   19590682.
82. Fernandez SV, Russo J (January 2010). "Estrogen and xenoestrogens in breast cancer". Toxicologic Pathology. 38 (1): 110–22. doi:10.1177/0192623309354108. PMC   2907875 . PMID   19933552.
83. "Living on Earth: War of the Sciences". Living on Earth . 2008-09-19. Retrieved 2023-12-15.
84. Aubrey, Allison (September 16, 2008). "FDA Weighs Safety Of Bisphenol A". NPR .
85. State of the Evidence, The Connection Between Breast Cancer and the Environment, 2008
86. US EPA, OA. "DDT Ban Takes Effect". www.epa.gov. Retrieved 2024-01-19.
87. Sonawane BR (September 1995). "Chemical contaminants in human milk: an overview". Environmental Health Perspectives. 103 Suppl 6 (S6): 197–205. doi:10.1289/ehp.95103s6197. JSTOR   3432374. PMC   1518901 . PMID   8549474.
88. Eskenazi B, Chevrier J, Rosas LG, Anderson HA, Bornman MS, Bouwman H, et al. (September 2009). "The Pine River statement: human health consequences of DDT use". Environmental Health Perspectives. 117 (9): 1359–67. doi:10.1289/ehp.11748. PMC   2737010 . PMID   19750098.
89. Clapp RW, Jacobs MM, Loechler EL (2008). "Environmental and occupational causes of cancer: new evidence 2005-2007". Reviews on Environmental Health. 23 (1): 1–37. doi:10.1515/REVEH.2008.23.1.1. PMC   2791455 . PMID   18557596.
90. "Breast Cancer Facts & Figures 2005–2006" (PDF). American Cancer Society. Atlanta. 2005. Archived from the original (PDF) on 2007-06-13. Retrieved 2007-04-26.
91. California Environmental Protection Agency: Air Resources Board (2005). Proposed Identification of Environmental Tobacco Smoke as a Toxic Air Contaminant (Report). UCSF: Center for Tobacco Control Research and Education.; on January 26, 2006, the Air Resources Board, following a lengthy review and public outreach process, determined ETS to be a Toxic Air Contaminant (TAC).
92. CDCTobaccoFree (2022-05-03). "Surgeon General's Reports on Smoking and Health". Centers for Disease Control and Prevention. Retrieved 2024-01-19.
93. J. Russo, I. Russo. "Molecular Basis of Breast Cancer: Prevention and Treatment," Springer, 2003
94. Russo J, Russo IH (2003). Molecular basis of breast cancer: prevention and treatment: with 338 figures and 63 tables. Berlin: Springer. ISBN   978-3-540-00391-5.
95. Cohen M, Lippman M, Chabner B (October 1978). "Role of pineal gland in aetiology and treatment of breast cancer". Lancet. 2 (8094): 814–6. doi:10.1016/S0140-6736(78)92591-6. PMID   81365. S2CID   10052553.
96. Blask DE, Brainard GC, Dauchy RT, Hanifin JP, Davidson LK, Krause JA, et al. (December 2005). "Melatonin-depleted blood from premenopausal women exposed to light at night stimulates growth of human breast cancer xenografts in nude rats". Cancer Research. 65 (23): 11174–84. doi: 10.1158/0008-5472.CAN-05-1945 . PMID   16322268.
97. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE, et al. (2009). "Insulin, insulin-like growth factor-I and risk of breast cancer in postmenopausal women". J Natl Cancer Inst. 101 (1): 48–60. doi:10.1093/jnci/djn415. PMC   2639294 . PMID   19116382.
    • Lay summary in: "Low Melatonin Associated with Increased Risk of Breast Cancer in Postmenopausal Women". Science Daily. June 16, 2008.
98. "Press release No. 180: IARC Monographs Programme finds cancer hazards associated with shiftwork, painting and firefighting". International Agency for Research on Cancer. 2007-12-05. Archived from the original on 2008-04-11.
99. Schernhammer ES, Schulmeister K (March 2004). "Melatonin and cancer risk: does light at night compromise physiologic cancer protection by lowering serum melatonin levels?". British Journal of Cancer. 90 (5): 941–3. doi:10.1038/sj.bjc.6601626. PMC   2409637 . PMID   14997186.
100. Hansen J (January 2001). "Increased breast cancer risk among women who work predominantly at night". Epidemiology. 12 (1): 74–7. doi: 10.1097/00001648-200101000-00013 . PMID   11138824. S2CID   34390800.
101. Hansen J (October 2001). "Light at night, shiftwork, and breast cancer risk". Journal of the National Cancer Institute. 93 (20): 1513–5. doi: 10.1093/jnci/93.20.1513 . PMID   11604468.
102. Schernhammer ES, Laden F, Speizer FE, Willett WC, Hunter DJ, Kawachi I, Colditz GA (October 2001). "Rotating night shifts and risk of breast cancer in women participating in the nurses' health study". Journal of the National Cancer Institute. 93 (20): 1563–8. doi: 10.1093/jnci/93.20.1563 . PMID   11604480.
103. Navara KJ, Nelson RJ (October 2007). "The dark side of light at night: physiological, epidemiological, and ecological consequences" (PDF). Journal of Pineal Research. 43 (3): 215–24. doi:10.1111/j.1600-079X.2007.00473.x. PMID   17803517. S2CID   11860550. Archived from the original (PDF) on 2011-12-14.
104. Kacimi S, Elgenidy A, Cheema HA, Ould Setti M, Khosla AA, Benmelouka AY, Aloulou M, Djebabria K, Shamseldin LS, Riffi O, Mesli NS, Sekkal HZ, Afifi AM, Shah J, Ghozy S (2022-07-20). "Prior Tonsillectomy and the Risk of Breast Cancer in Females: A Systematic Review and Meta-analysis". Frontiers in Oncology. 12. doi: 10.3389/fonc.2022.925596 . ISSN   2234-943X. PMC   9350012 . PMID   35936707.
105. Vainshtein J (July 2008). "Disparities in breast cancer incidence across racial/ethnic strata and socioeconomic status: a systematic review". Journal of the National Medical Association. 100 (7): 833–9. doi:10.1016/S0027-9684(15)31378-X. PMID   18672561.
106. Wisconsin Cancer Incidence and Mortality, 2000-2004 (PDF) (Report). Wisconsin Department of Health and Family Services, Division of Public Health, Bureau of Health Information and Policy. September 2007. Archived from the original (PDF) on 2008-05-30.
107. Tammemagi CM (February 2007). "Racial/ethnic disparities in breast and gynecologic cancer treatment and outcomes". Current Opinion in Obstetrics & Gynecology. 19 (1): 31–6. doi:10.1097/GCO.0b013e3280117cf8. PMID   17218849. S2CID   1445353.
108. Hirschman J, Whitman S, Ansell D (April 2007). "The black:white disparity in breast cancer mortality: the example of Chicago". Cancer Causes & Control. 18 (3): 323–33. doi:10.1007/s10552-006-0102-y. PMID   17285262. S2CID   3349878.
109. Villa, Amanda (2007-10-24). "Breast cancer rates differ in races". Badger Herald . Archived from the original on 2007-10-25.
110. Benjamin M, Reddy S, Brawley OW (March 2003). "Myeloma and race: a review of the literature". Cancer and Metastasis Reviews. 22 (1): 87–93. doi:10.1023/A:1022268103136. PMID   12716040. S2CID   27614206.
111. Zuckerman D (2009). "The Ethics of Inclusion and Exclusion in Clinical Trials: Race, Sex, and Age". In Ravitsky V, Fiester A, Caplan A (eds.). The Penn Center Guide to bioethics. Springer. ISBN   978-0-8261-1522-5.
112. Demicheli R, Retsky MW, Hrushesky WJ, Baum M, Gukas ID, Jatoi I (November 2007). "Racial disparities in breast cancer outcome: insights into host-tumor interactions". Cancer. 110 (9): 1880–8. doi: 10.1002/cncr.22998 . PMID   17876835. S2CID   46360199.
113. Hausauer AK, Keegan TH, Chang ET, Clarke CA (2007). "Recent breast cancer trends among Asian/Pacific Islander, Hispanic, and African-American women in the US: changes by tumor subtype". Breast Cancer Research. 9 (6): R90. doi: 10.1186/bcr1839 . PMC   2246193 . PMID   18162138.
114. Gierach GL, Lissowska J, Garcia-Closas M, Yang XR, Figueroa JD, Anzick S, et al. (April 19, 2010). "Relationship of mammographic density with breast cancer subtypes". Cancer Research . 70. doi:10.1158/1538-7445.AM10-2779.
115. "Breast Density Change Linked to Cancer Development in WHI Hormone Replacement Study". Georgetown University Medical Center . 2010-04-21. Archived from the original on 2010-06-09. Retrieved 2010-04-23.
116. Masarwah A, Auvinen P, Sudah M, Rautiainen S, Sutela A, Pelkonen O, et al. (July 2015). "Very low mammographic breast density predicts poorer outcome in patients with invasive breast cancer". European Radiology. 25 (7): 1875–82. doi:10.1007/s00330-015-3626-2. PMID   25735512. S2CID   25084312.
117. Lin, GH; Brusick, DJ (Jul 1986). "Mutagenicity studies on FD&C red No.3". Mutagenesis. 1 (4): 253–259. doi:10.1093/mutage/1.4.253. PMID   2457780 . Retrieved 12 February 2024.
118. Dees C, Askari M, Garrett S, Gehrs K, Henley D, Ardies CM (April 1997). "Estrogenic and DNA-damaging activity of Red No. 3 in human breast cancer cells". Environmental Health Perspectives. 105 (Suppl 3). Environmental Health Perspectives, Vol. 105: 625–32. doi:10.2307/3433381. JSTOR   3433381. PMC   1469907 . PMID   9168006.
119. Heng B, Glenn WK, Ye Y, Tran B, Delprado W, Lutze-Mann L, et al. (October 2009). "Human papilloma virus is associated with breast cancer". British Journal of Cancer. 101 (8): 1345–50. doi:10.1038/sj.bjc.6605282. PMC   2737128 . PMID   19724278.
120. Lawson JS, Günzburg WH, Whitaker NJ (June 2006). "Viruses and human breast cancer". Future Microbiology. 1 (1): 33–51. doi:10.2217/17460913.1.1.33. PMID   17661684.
121. Joshi D, Buehring GC (August 2012). "Are viruses associated with human breast cancer? Scrutinizing the molecular evidence". Breast Cancer Research and Treatment. 135 (1): 1–15. doi:10.1007/s10549-011-1921-4. PMID   22274134. S2CID   1310301.
122. Lawson JS, Tran D, Rawlinson WD (2001). "From Bittner to Barr: a viral, diet and hormone breast cancer aetiology hypothesis". Breast Cancer Research. 3 (2): 81–5. doi: 10.1186/bcr275 . PMC   138675 . PMID   11250750.
123. Taneja P, Frazier DP, Kendig RD, Maglic D, Sugiyama T, Kai F, et al. (July 2009). "MMTV mouse models and the diagnostic values of MMTV-like sequences in human breast cancer". Expert Review of Molecular Diagnostics. 9 (5): 423–40. doi:10.1586/erm.09.31. PMC   2759974 . PMID   19580428.
124. "Induced abortion does not increase breast cancer risk". World Health Organization . June 2000. Archived from the original on 2007-12-14. Retrieved 2007-12-24.
125. "Bras and breast cancer risk". Cancer Research UK. Archived from the original on April 6, 2012. Retrieved April 6, 2013.
126. "Breast cancer". A.D.A.M. Medical Encyclopedia, U.S. National Library of Medicine. November 17, 2012. Archived from the original on December 18, 2013. Retrieved April 6, 2013.
127. Surendran, Aparna (March 2004). "Studies linking breast cancer to deodorants smell rotten, experts say". Nature Medicine . 10 (3): 216. doi: 10.1038/nm0304-216b . ISSN   1078-8956. PMID   14991030.
128. Gorski D (6 October 2014). "Breast cancer myths: No, antiperspirants do not cause breast cancer". Science-Based Medicine.
129. Namer M, Luporsi E, Gligorov J, Lokiec F, Spielmann M (September 2008). "[The use of deodorants/antiperspirants does not constitute a risk factor for breast cancer]" [The use of deodorants/antiperspirants does not constitute a risk factor for breast cancer]. Bulletin du Cancer (Comprehensive literature review) (in French). 95 (9): 871–80. doi:10.1684/bdc.2008.0679 (inactive 1 November 2024). PMID   18829420.
130. Potashnik G, Lerner-Geva L, Genkin L, Chetrit A, Lunenfeld E, Porath A (May 1999). "Fertility drugs and the risk of breast and ovarian cancers: results of a long-term follow-up study". Fertility and Sterility. 71 (5): 853–9. doi: 10.1016/S0015-0282(99)00085-0 . PMID   10231045.
131. Yalom M (1997). A history of the breast. New York: Alfred A. Knopf. p.  234. ISBN   978-0-679-43459-7.
132. Olson JS (2002). Bathsheba's breast: women, cancer & history. Baltimore: The Johns Hopkins University Press. pp.  32–33. ISBN   978-0-8018-6936-5.

External links

• GeneReviews/NCBI/NIH/UW entry on BRCA1 and BRCA2 Hereditary Breast/Ovarian Cancer
• Breast cancer database at Silent Spring Institute